NeoGenomics Stock Just Turned Its First Profit, Creating an Optimal Entry Point
NeoGenomics (NEO) is a leading cancer genetics diagnostics lab. Its stock recently hit a new 2-year high.
Analyst sentiment is predominantly bullish, with consensus price targets up to $35 and recent profitability marking a compelling entry point.
Valued at $2.2 billion, NeoGenomics (NEO) is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology, and molecular genetic testing. It services the needs of pathologists, oncologists, urologists, hospitals, and other reference laboratories throughout the United States.
I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. NEO checks those boxes. The Trend Seeker issued a new "Buy" signal on July 29. Since then, the stock has gained 26.39%.
Warren Buffett Says Peter Thiel Can Quit Giving Pledge If It's Too 'Woke' for Him, 'A Lot of Reasons Why Rich People Don't Like Other Rich People'
Elon Musk Says We're '1000% Going to Go Bankrupt' Without Al and Robots, 'We're Totally Screwed' as Interest on National Debt Tops $1 Trillion
Nvidia Reports $7.8 Billion in Q2 Gains on Equity Portfolio That Includes SpaceX, Intel, CoreWeave, and More
The stock recently traded at $19.27 with a 50-day moving average of $14.94.
Revenue is projected to grow 10.55% this year and another 10.07% next year.
Earnings are estimated to increase by 31.17% this year and an additional 13.68% next year.
The Wall Street analysts followed by Barchart give the stock 6 "Strong Buy," 1 "Moderate Buy" and 4 "Hold" opinions with price targets between $16 and $35.
Morningstar thinks the stock is 13% overvalued with a fair value of $15.27.
9,710 investors are following the stock on Seeking Alpha, which rates it a "Strong Buy."
TipRanks' analysts' price targets are between $16 and $21 with a consensus price target of $18.33 for a 5.55% gain.
Short interest is 12% of the float with 4.17 days to cover the float.
On July 28, the company announced it finally booked a profit. That makes this a very good entry point.
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculate should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.
